Perspective Therapeutics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Perspective Therapeutics reported Q2 2026 results with cash/investments of $237M (vs. $145M at year-end 2025), sufficient to fund operations into late 2027. The lead program VMT-α-NET in neuroendocrine tumors is advancing toward Phase 3 with 76 NET patients and 1 meningioma patient treated; Phase 3 site activation targeted year-end 2026 pending regulatory feedback. R&D expenses grew to $21.5M in Q2 2026 from $16.6M in Q2 2025; net loss was $26.8M ($0.22/share) vs. $21.5M ($0.29/share) in the prior year.
Why this rating
Cash runway extension and clinical progress are positive, but burn rate is high (~$230M annualized) relative to $237M balance. No transformational event; routine clinical/financial update.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.